Uncommon serum creatine phosphokinase and lactic dehydrogenase increase during diosmin therapy: two case reports

Giulia Milano, Silvia Leone, Carmen Fucile, Maria Laura Zuccoli, Andrea Stimamiglio, Antonietta Martelli, Francesca Mattioli, Giulia Milano, Silvia Leone, Carmen Fucile, Maria Laura Zuccoli, Andrea Stimamiglio, Antonietta Martelli, Francesca Mattioli

Abstract

Introduction: Short-term administration of diosmin is usually considered safe, with only minor side effects (stomach and abdominal pain, diarrhea, dermatological disorders, and headache) occasionally observed. Within a 4-year period, a general practitioner noticed 17 cases of mild, diosmin-induced side effects, two of which showed particular interest.

Cases presentation: Case 1: A 55-year-old Caucasian woman presented with chronic leg venous insufficiency. She was prescribed diosmin 450 mg twice a day. After 5 days of therapy, she developed pain in the legs (myalgia), and diosmin therapy was suspended. She made a spontaneous attempt of drug rechallenge and her leg pain reappeared. Thus, she underwent blood analysis, which showed elevation of creatine phosphokinase levels. Creatine phosphokinase values normalized only after prolonged discontinuation of the therapy. Case 2: A 79-year-old Caucasian man, who was diagnosed with acute hemorrhoidal syndrome. After 21 days of continuous diosmin treatment, increased levels of serum lactic dehydrogenase were detected. In both cases a comprehensive analysis of all possible causes for enzyme elevation was made.

Conclusions: A feasible hypothesis to explain these rare effects could be that exaggerated adrenergic activity occurred on microcirculation, leading to an excessive peripheral vasoconstriction and subsequent ischemic damage. An individual predisposition is strongly suggested. A concurrence of events was probably responsible for the elevation of nonspecific tissue necrosis markers. Physicians and patients must be aware of these rare, but possible, adverse drug reactions.

References

    1. Diosmin monograph. Altern Med Rev. 2004;9:308–311.
    1. Boudet C, Peyrin L. Comparative effect of tropolone and diosmin on venous COMT and sympathetic activity in rat. Arch Int Pharmacodyn Ther. 1986;283:312–320.
    1. Friesenecker B, Tsai AG, Intaglietta M. Cellular basis of inflammation, edema and the activity of Daflon 500mg. Int J Microcirc Clin Exp. 1995;15:17–21.
    1. Ramelet AA. Pharmacologic aspects of a phlebotropic drug in CV1-associated edema. Angiology. 2000;51:19–23.
    1. Le Dévéhat C, Khodabandehlou T, Vimeux M, Kempf C. Evaluation of haemorheological and microcirculatory disturbances in chronic venous insufficiency: activity of Daflon 500mg. Int J Microcirc Clin Exp. 1997;17:27–33.
    1. Labrid C. A lymphatic function of Daflon 500mg. Int Angiol. 1995;14:36–38.
    1. Manthey JA, Grohmann K, Guthrie N. Biological properties of citrus flavonoids pertaining to cancer and inflammation. Curr Med Chem. 2001;8:135–153.
    1. Katsenis K. Micronized purified flavonoid fraction (MPFF): a review of its pharmacological effects, therapeutic efficacy and benefits in the management of chronic venous insufficiency. Curr Vasc Pharmacol. 2005;3:1–9.
    1. Cova D, De Angelis L, Giavarini F, Palladini G, Perego R. Pharmacokinetics and metabolism of oral diosmin in healthy volunteers. Int J Clin Pharmacol Ther Toxicol. 1992;30:29–33.
    1. Drugcite: Adverse event categories for diosmin. [ ]
    1. Naranjo CA, Busto U, Sellers EM, Sandor P, Ruiz I, Roberts EA, Janecek E, Domecq C, Greenblatt DJ. A method for estimating the probability of adverse drug reactions. Clin Pharmacol Ther. 1981;30:239–245.
    1. Meyer OC. Safety and security of Daflon 500mg in venous insufficiency and in hemorrhoidal disease. Angiology. 1994;45:579–584.
    1. Kumar RM, Van Gompel JJ, Bower R, Rabinstein AA. Spontaneous intraventricular hemorrhage associated with prolonged diosmin therapy. Neurocrit Care. 2011;14:438–440.
    1. Sher E, Codignola A, Biancardi E, Cova D, Clementi F. Amine uptake inhibition by diosmin and diosmetin in human neuronal and neuroendocrine cell lines. Pharmacol Res. 1992;26:395–402.
    1. Middleton E, Kandaswami C, Theoharides TC. The effects of plant flavonoids on mammalian cells: implications for inflammation, heart disease, and cancer. Pharmacol Rev. 2000;52:673–751.

Source: PubMed

3
Abonnieren